Author: Marissa Dean

Zimbabwe Tobacco Sales Bring in Millions

Photo: Taco Tuinstra
Zimbabwe’s tobacco revenue has reached $258 million, 19 percent more than in the comparable 2022 period, reports NewsDay.
“Income/revenue to farmers increased by 19 percent from $216 million to $258 million this year owing to the tobacco value chain transformation strategy, which is currently in motion, and this is likely to increase the country’s chances of achieving the objectives of V30,” said John Basera, permanent secretary of Lands, Agriculture, Fisheries, Water and Rural Resettlement, referring to the government’s strategy to reduce poverty. “Tobacco output grew marginally by 1 percent from 211,100,219 kg produced during the 2020/2021 production season to 212,711,370 kg in the 2021/2022 season.”
Tobacco production is expected to increase by 9 percent from 212,703 tons.
Total deliveries were up by 18 percent to 86.14 million kg compared to 72.21 million kg in the same period last year while the average price firmed by 1 percent from $2.97 per kilogram in 2022 to $3 per kilogram in the same period this year.
May 2, 2023
Ban on Nonprescription Vape Imports

Image: Tobacco Reporter archive
The Australian government announced that it will ban the importation of all nonprescription vaping products—including those that do not contain nicotine. The new legislation is billed as containing the most significant tobacco and vaping control measures in the country in a decade.
The announcement today clarifies last week’s announcement of a crackdown on illegal vaping. This time, the government said it would now include a total ban on nonprescription vaping products.
To tackle youth vaping, minimum quality standards for vapes will be introduced, including restricting flavors, colors and other ingredients. Vape products will require pharmaceutical-like packaging, and the allowed nicotine concentrations and volumes will be reduced.
All single-use, disposable vapes will be banned, according to The Guardian.
Speaking on ABC’s Q&A on Monday night, Australia’s health minister, Mark Butler, said that the tobacco industry was trying to create a “new generation of nicotine addicts” through vaping and that he was “determined to stamp out this public health menace.”
The move follows an inquiry into vaping reforms led by the drugs regulator, the Therapeutic Goods Administration, with submissions from health professional bodies, public health associations, individual health professionals and university researchers that overwhelmingly support tightening border controls.
Many public health experts and bodies suggested to the inquiry that border controls should also be placed on non-nicotine vaping products to prevent mislabeling and exploitation of import loopholes. It follows manufacturers falsely labeling products containing nicotine as “nicotine-free” to get around import restrictions, leaving children easily able to buy vapes, often unknowingly inhaling nicotine and becoming addicted.
The government will also work with states and territories to end vape sales in convenience stores and other retailers. Prescriptions for nicotine vaping products for smokers trying to quit tobacco will be made easier to obtain, with stronger standards around the vaping products that can be bought in pharmacies so people can be assured of the content of the products.
Butler said he will expand on the reforms in a speech to the National Press Club on Tuesday, where he is expected to say vaping has become “the biggest loophole in Australian history” and announce that the following Tuesday’s federal budget will include AUD234 million ($156.22 million) in funding for tobacco and vaping reforms, the biggest since plain packaging of tobacco products was introduced.
May 2, 2023
22nd Century Signs Deal with Old Pal

Image: Tobacco Reporter archive
22nd Century announced its second exclusive license, manufacturing and distribution agreement in the hemp/cannabis industry, signed with Old Pal, a consumer company started in California and now operating in eight U.S. states.
“Old Pal is the second leading consumer hemp/cannabis brand to adopt 22nd Century’s innovative strategic license, manufacturing and distribution agreement. This model enables brands to focus on product development, customer engagement and marketing while we provide expansive access to mass market channels urgently seeking new, high-margin, high-velocity products to meet growing consumer demand,” said James A. Mish, CEO of 22nd Century.
Initially launched in California in 2018, Old Pal gained recognition for its nostalgic branding. In addition, Old Pal’s continuously growing line of apparel, accessories and home goods has firmly established it as a prominent cultural figure in the world of cannabis, according to 22nd Century.
The exclusive license with 22nd Century covers Old Pal branded non-delta-9 THC, hemp-derived cannabinoid consumer products and accessories. Similar to 22nd Century’s first single-source integrated production, sales and distribution agreement in hemp/cannabis, signed with Cookies, the Old Pal agreement will leverage 22nd Century’s formulation, ingredient and manufacturing infrastructure plus the company’s turn-key sales and distribution platform for alternative consumer products in a complete go-to-market solution.
Combined, the company estimates that its agreements with Cookies and Old Pal represent more than $140 million in revenue opportunity with attractive margins over the terms of the contracts. 22nd Century is now advancing its initial mass market retail efforts for these products across the United States, leveraging a network of more than 200 wholesale distributors. The company continues to pursue additional exclusive license opportunities with industry brands interested in its innovative integrated solution.
May 2, 2023
JT Reports ‘Solid’ First-Quarter Results

Image: Tobacco Reporter archive
Japan Tobacco (JT) reported revenue of ¥665.3 billion ($4.86 billion) in the first quarter of 2023, up 14.4 percent over the comparable 2022 quarter.
Core revenue at constant currency exchange rates increased by 6.2 percent to ¥594.6 billion. Adjusted operating profit at constant exchange rates increased by 5.1 percent to ¥204.7 billion. On a reported basis, adjusted operating profit increased by 14.6 percent to ¥223.4 billion. Operating profit increased by 15.7 percent to ¥206.4 billion. Profit increased by 16.6 percent to ¥144.7 billion.
“JT Group delivered solid results in the first quarter, building on the positive momentum across its businesses,” said Masamichi Terabatake, president and CEO of JT. “Robust pricing in the tobacco business continued to drive the strong performance of the group.
“In line with our plan to increase our presence in HTS (heated-tobacco sticks) and establish the foundations for JT Group’s future earnings growth, we successfully launched Ploom X in Italy and Lithuania in April after an encouraging rollout in the U.K. We are making good progress for additional international launches, with a rollout in Portugal planned for mid-May.
“Guided by the group’s management principle, which is to pursue the 4S model, and considering the recently announced JT Group Purpose, we will continue to take all necessary decisions to address operational uncertainties, such as regulatory changes, economic instabilities and volatile foreign exchange rates.”
May 2, 2023
As Smoking Declines, More Adults Switching

Image: Tobacco Reporter archive
U.S. cigarette smoking dropped to another all-time low last year, with one in 9 adults saying they were current smokers, according to government survey data released April 27. Meanwhile, electronic cigarette use rose, to about one in 17 adults.
The preliminary findings from the U.S. Centers for Disease Control and Prevention (CDC) are based on survey responses from more than 27,000 adults.
Last year, the percentage of adult smokers dropped to about 11 percent, down from about 12.5 percent in 2020 and 2021. The survey findings are sometimes revised after further analysis, and the CDC is expected to release final 2021 data soon.
E-cigarette use rose to nearly 6 percent last year, from about 4.5 percent the year before, according to survey data.
May 1, 2023
Bangladesh Urged Against Interference

Image: Tobacco Reporter archive
Bangladesh should monitor the tobacco industry’s attempts to influence the formulation and implementation of graphic health warnings, according to a new study in the British Medical Journal’s Tobacco Control, reports United News of Bangladesh.
The study, “Tobacco Industry Interference to Undermine the Development and Implementation of Graphic Health Warnings in Bangladesh,” examines the tobacco industry’s efforts to “delay and weaken” the implementation of graphic health warnings in Bangladesh.
The Bangladesh Cigarette Manufacturers’ Association was the most active industry actor in “interfering” with the process, according to the study, while BAT Bangladesh was most active and the only company that acted alone to thwart graphic health warning implementation.
The study urges the government to adopt the World Health Organization Framework Convention on Tobacco Control’s Article 5.3 guidelines and make their implementation a policy priority.
May 1, 2023
Filipinos Warned Against Disposed Cigs

Image: Andrii Yalanskyi | Adobe Stock
The Philippines Bureau of Customs (BOC)-Port of Zamboanga has warned the public against buying cigarettes that have disposed of by the agency, reports the Philippine News Agency.
The confiscated smuggled cigarettes are sprayed with pesticides, according to Mike Lanza, the customs intelligence and investigation service chief of BOC-Zamboanga.
“Hundreds of people were waiting to salvage packs of cigarettes,” Lanza said, referring to a large-scale destruction of illegal cigarettes completed on April 28, which took place at a sanitary landfill in Barangay Salaan in Zamboanga City. “The drivers of the dump trucks had to stop to avoid accidents.”
According to the BOC, individuals will pay scavengers for each pack of cigarettes they can recover. “They sell the cigarettes to community sundry stores at cheaper prices,” said Arthur Sevilla, BOC-Port of Zamboanga acting district collector.
The confiscated cigarettes are drenched in water and repeatedly crushed by heavy equipment, but scavengers search for packs that may have managed to stay dry.
May 1, 2023
The Pharmacology of Nicotine

Photo: Richard Villalon
The fascinating workings of a widely misunderstood chemical
By Grant Churchill
In this article, I will describe the pharmacology of nicotine. I will guide you along nicotine’s journey, starting with how it gets into a person, explain what it does once inside by interacting with specific receptors and finally, how it is inactivated and leaves.
Due to its chemical properties, nicotine can exist in two forms, depending on acidity, which controls its ability to be absorbed and, in turn, the effectiveness of delivery by different routes of administration. For example, certain forms of smoked tobacco must be inhaled to absorb nicotine, such as cigarettes, whereas others, such as cigar and pipe tobacco, are not inhaled but nicotine is still absorbed.
It might be useful for the reader to know where I’m coming from in writing this article. I’ve got a professional interest in how drugs work as I do research and teach in this area and find the pharmacology of nicotine fascinating and convey this to medical students. I’ve also got a personal interest as both my parents smoked and died from cancer. So, I wonder if vapes were available 40 years ago, would my parents still be alive? And now, should I be concerned that my adult son is vaping?
Routes and Rates
I’ll now describe in more detail how nicotine gets into the body and then the brain. This depends on the fascinating interplay between the route of administration and the chemical formulation, for example, free base or salt of nicotine. Regarding the route of administration, one can have an intuitive and qualitative understanding by considering the number of barriers and distance from the site of application to the brain.
When inhaled, nicotine has a short journey with few barriers as it is absorbed into the oxygenated arterial blood and goes from the heart to the brain within 10 seconds.
When swallowed, nicotine has a much longer journey with several barriers as it has to make its way through the stomach on to the small intestine before it can be absorbed into the bloodstream. Then it is in the deoxygenated venous blood that goes to the liver, then through veins to the heart, then through the lungs, where it finally meets the starting point for the inhaled nicotine. Importantly, the liver acts as a paper shredder for drugs and metabolizes them before they are delivered to the rest of the body.
When applied by a patch, the skin provides an additional barrier before nicotine can enter the bloodstream. Surprisingly, an intravenous injection of nicotine results in a slower route to the brain than inhalation.
For the intuitive understanding of the routes and rates, one can think about the physiological role of each system. The job of the lungs is to absorb large amounts of oxygen and quickly deliver it to the brain, the importance of which is driven home by considering that consciousness is lost within tens of seconds if inhibited. In contrast, the job of the gastrointestinal tract is to absorb food for energy, which is not needed at the pace of oxygen. Moreover, the job of the liver has evolved to protect us from the remarkably diverse and potentially harmful chemicals we consume in our diets, and in this regard, a drug is just another nonfood or non-nutrient to be inactivated and removed.
The uptake of nicotine can be more precisely studied quantitatively by monitoring nicotine in the blood and graphing this over time. This reveals an initial increase, a peak and then a tapering off, and numbers can be put to the time and concentration at the peak and the area under the curve. The hit comes from a combination of the speed of the peak and the maximum concentration, and the craving comes from when the concentration falls below a critical activity threshold. The different routes of administration show characteristic concentration over time profiles, with inhaled nicotine showing a fast peak within minutes whereas a patch-delivered nicotine shows a slow increase, taking an hour to peak. This has implications in the user experience and the success of nicotine-replacement therapies for tobacco harm reduction. The rate of decrease in nicotine concentration is similar for all routes of administration due to the same elimination mechanisms: a combination of metabolism by the liver and excretion by the kidney into the urine.
Crossing Barriers
The chemical formulation of nicotine as a salt or free base has a major impact on its uptake into the body as only the latter gets in. The chemical basis of this can be understood by considering a vinaigrette, which forms two layers, with the oil floating on a layer of vinegar and table salt (sodium chloride) dissolving only in the vinegar. This demonstrates that molecules can be watery or oily and only mix with their own kind, as summed up by the adage that oil and water don’t mix. Bringing this back to biology, the barriers to uptake of nicotine are cells that form layers like brick walls to separate the contents of our gastrointestinal tract from blood and blood from the organs. The cell’s barrier is its surface membrane called a bilayer, which is an inside out soap bubble with a watery surface and an oily interior forming the barrier. A water-loving nicotine salt cannot cross the oily interior whereas the oily free base of nicotine easily crosses.
The ability of nicotine free base to easily cross cell membranes is the mechanistic explanation of why nicotine can be absorbed from pipe and cigar smoke held in the mouth whereas cigarette smoke must be inhaled. The processing of the tobacco alters the chemical composition and acidity, resulting in cigarette flue-cured tobacco being acidic with nicotine salt whereas air-cured pipe tobacco is alkaline with nicotine free base. For a fuller explanation, we must again consider how chemistry interacts with biology. Smoke from acidic tobacco (nicotine salt) is less harsh and irritating and can be inhaled deeply into the lungs, where the large surface area (approximately the size of a tennis court) compensates for the inability of the salt to cross membranes.
Nicotine is always present in both forms, and the acidity controls the relative amounts of salt to free base with only a tenth of a percent in cigarette smoke being the free base compared to 50 percent in pipe smoke.
The trade-offs between the amount of nicotine that is bioavailable and how deeply it can be inhaled to take advantage of the large surface area of the lungs can also explain the nicotine salt craze in vapes. Nicotine salt formed by adding benzoic acid leads to a “smooth” taste, enabling deep inhalation of higher concentrations of nicotine.
How it Works Inside
Now that nicotine is in the body, I’ll describe its effects and how it is active. Nicotine affects cognition, body function and mood. The effects of nicotine on cognition relate to attention and memory and it has been suggested to be a “work” drug as opposed to what most of society would think of as a recreational or “fun” drug. The effects of nicotine on body function mostly relate to heart rate and blood pressure. The effects of nicotine on mood are relaxation and euphoria, arguably two of its major effects as nicotine stimulates a reward pathway in our brains the causes one brain region to stimulate other regions involved in emotion by releasing the neurotransmitter dopamine. Neurotransmitters are chemical messengers that enable communication between the brain cells termed neurons. Very generally, dopamine signals reward or the anticipation of reward—think sex, drugs and rock ’n’ roll, and these days, smartphones—which leads to pleasure and risk of dependence. Nicotine itself acts by mimicking the neurotransmitter acetylcholine, which is involved in learning, memory and attention, which fits with its subjective effects mentioned above.
Remarkably, all the diverse actions of nicotine arise from it acting on the same pharmacological target: the nicotinic acetylcholine receptor. This receptor spans the surface membrane of a cell and acts as a gated pore that allows ions such as sodium to flow through and trigger a wave of voltage change that sweeps from one end of the cell to the other. The binding of acetylcholine, or nicotine, results in opening and turning on the signal—but with prolonged presence, the gate on the pore jams shut in what is termed “desensitization.”
So, nicotine has time-dependent effects: Over a period of minutes, the nicotinic acetylcholine receptors open and release dopamine, but after several hours in the presence of nicotine, many of the receptors desensitize, dopamine levels fall, and more nicotine is required to return to the higher level of dopamine. Over a period of weeks, the neuron responds by increasing the number of nicotinic acetylcholine receptors, but most are desensitized, and if nicotine is no longer present, dopamine levels fall, giving rise to physiological withdrawal and addiction. Addiction at the molecular level is related to the structure of the nicotinic acetylcholine receptor, which is made up of five cylindrical subunits arranged side by side in a circle to form the pore. Each subunit is given a Greek letter designation, and in a mouse model, addiction relates to the presence or absence of the beta subunit.
Chemical Inactivation
The pharmacological effects of nicotine wear off with time, not from the above desensitization mechanisms but through chemical inactivation and excretion. Nicotine in the blood has a half-life, the time for a given concentration to be reduced by half, of about two hours. Nicotine declines over time through processes common to all drugs in which the underlying principle is to convert a drug from an oily compound to one that is watery. Water is watery due to it being composed of hydrogen and oxygen, therefore introducing oxygen into nicotine makes it watery.
This chemical transformation occurs in the liver by the enzyme (a molecular machine) cytochrome P450, which forms the major metabolite cotinine. As cotinine has a half-life of about a day, it can be used to examine past nicotine exposure, often by health insurance companies. Cytochrome P450 is a family of enzymes, and different forms are more or less active in converting nicotine to cotinine; the specific form varies between individuals, and certain forms are more frequent in a given ethnic group. For example, a less active form of the enzyme is more prevalent in individuals with Black or Asian heritage. Cotinine or its metabolites are finally removed from the body through the action of the kidneys and excreted into the urine. Again, the effect of acidity on nicotine can be employed by acidifying the urine to increase the fraction of salt, which cannot be reabsorbed back by the body, which thereby increases nicotine excretion.
Addressing Misunderstandings
Lastly, there are many controversies surrounding nicotine based on misunderstanding, half-truths and myths. The major health consequences of smoking are due to chemicals other than nicotine produced during combustion of tobacco, so other methods of nicotine delivery provide for tobacco harm reduction. For example, the relative health harms are such that vaping is a method for smoking cessation endorsed by the National Health Service in the U.K. and promoted as such by the government based on the best current scientific evidence.
Nicotine was used as a pesticide and can be toxic, but as Paracelsus famously stated, the dose makes the poison; any chemical can be toxic, including seemingly innocuous water, or an exceptionally toxic substance such as Botox can be used safely at a lowered concentration. Nicotine may have bona fide therapeutic use beyond smoking cessation in Alzheimer’s disease, Parkinson’s disease, schizophrenia and obesity. Intriguing evidence has been published regarding all these disorders, but the studies were small, leading to equivocal results.
Larger studies are needed, but the demonization of the tobacco industry for past wrongs is tainting and hampering the ability of scientists and physicians to obtain funding and conduct large, definitive trials. Given that psychedelic drugs, which were made illegal and vilified in the 1960s, are experiencing a renaissance to treat depression and post-traumatic stress disorder, there is hope that nicotine can be separated from smoked tobacco and used or not based on the evidence.
Grant Churchill is a professor of chemical pharmacology at the University of Oxford.

May 1, 2023
Betting on Weed

Photo: contentdealer
BAT has further increased its investments in the cannabis industry.
By Stefanie Rossel
In its endeavor to transform its business, initiated in 2020 under the slogan “A better tomorrow,” BAT is increasingly focusing on the cannabis sector to diversify beyond tobacco and nicotine. Two years after its first venture into the hemp market, the group currently has partial stakes in 13 cannabis startups, more than any other tobacco company, according to Seeking Alpha, a financial services provider.
BAT’s most recent move in this direction is a joint venture with Denver, Colorado-based cannabidiol (CBD) producer Charlotte’s Web Holdings in early April. BAT’s subsidiary AJNA Bio Sciences, a botanical drug development company focused on mental health and neurological disorders, has teamed up with Charlotte’s Web and is contributing $10 million as the joint venture’s initial investor. AJNA was co-founded and is partially owned by its president, Joel Stanley, the former CEO and chairman of Charlotte’s Web, together with other founding members of Charlotte’s Web.
The aim of the cooperation is to develop from propriety Charlotte’s Web hemp genetics a botanical drug targeting a neurological condition and pursue approval by the U.S. Food and Drug Administration. While the joint venture did not disclose the neurological condition, observers suspect that the drug is aimed at the treatment of seizure disorders. Charlotte’s Web is also the name of a hemp strain from which an oil can be made that can be used to treat Dravet syndrome and other epilepsy diseases.
The strain, which contains 17 percent CBD and 0.5 percent of the psychoactive ingredient tetrahydrocannabinol, was bred in 2011 by the Stanley brothers to treat a young girl suffering from a severe form of pediatric epilepsy that did not respond to commonly used anti-epileptic drugs. Encouraged by the patient’s positive response to their CBD oil, the brothers established a nonprofit organization to give seizure patients access to high-quality cannabis with a high CBD content. With their advocacy, they helped change laws and public perceptions relating to plant-based solutions. Nevertheless, their product did not become the first treatment derived from cannabis plants to receive FDA authorization. That honor fell to Epidiolex, which contains only CBD and was approved by the agency in 2018.
The joint venture, in which BAT holds a 20 percent stake and Charlotte’s Web and AJNA have a 40 percent stake each, will be led by representatives of all three companies. Its clinical and regulatory strategy will be led by Orrin Devinsky, who was a principal investor in the FDA approval of Epidiolex. Apart from being AJNA’s chief medical advisor, he is also the director of New York City University Langone’s Comprehensive Epilepsy Center. The joint venture wants to file an investigational new drug application and commence phase I clinical development in 2023.
In November 2022, BAT paid £48.2 million ($60.36 million) for a 19.9 percent stake in Charlotte’s Web, a leading company in hemp extract products and the only publicly traded CBD B Corp-certified company. According to its latest financial reports, Charlotte’s Web generated revenues of $74.13 million in 2022.
In mid-March, a major shareholder urged BAT to move its primary stock market listing from London to New York. About 60 percent of BAT’s profits come from the U.S. while only 1 percent is generated in the U.K. With a move to the U.S., analysts argued, the FTSE 100-listed company would not only gain an investor base with greater appreciation of reduced-risk products but also be better equipped if it wanted to venture into the cannabis markets. U.K. law prohibits a company from listing if its profits are sourced from recreational cannabis, even if they are earned in a jurisdiction where marijuana is legal. Although similar restrictions currently exist in the U.S., analysts expect these issues to be addressed in the near future.
With its recent investments, BAT continues its exploration of the cannabis business, which started in March 2021, when it acquired a minority stake in Organigram Holdings of Canada for CAD221 million ($175 million at the time). Canada legalized cannabis in October 2018. Through a number of acquisitions and organic growth, Organigram has since become the second-largest licensed cannabis producer in Canada.
Stefanie Rossel is Tobacco Reporter’s editorial contributor. An experienced trade journalist, she combines sharp reporting skills with in-depth knowledge of the tobacco and vapor industries. Prior to joining Tobacco Reporter, Stefanie was editor-in-chief at Tobacco Journal International, where she worked for a decade. Fluent in English, German and French, Stefanie covers tobacco news around the world. She is based in Germany.

May 1, 2023
Incentivizing Innovation

How the EU’s ambition to overhaul its packaging legislation might impact the tobacco industry.
By George Gay
As I understand things, a human body can be composted, in those places where this practice is legal, within about 30 days. On the other hand, my experience is that some starched-based “fully compostable” packaging can take more than 600 days to break down completely. Such a difference in composting times gives pause, I think, and I have long felt that the messaging around compostable packaging could do with some fine-tuning.

So I was encouraged, at least on behalf of those living in the EU and countries that follow EU packaging rules, to see that the EU Commission, as part of its proposed overhaul of its packaging legislation, is seeking to clear up the confusion around bio-based, biodegradable and compostable plastics.

In an end-of-November press note titled “European Green Deal: Putting an end to wasteful packaging, boosting reuse and recycling,” the commission announced its proposed revision (see https://bit.ly/3F6PRfp) of the EU’s legislation on packaging and packaging waste, saying that while the production and use of bio-based, biodegradable and compostable plastics had been increasing, a number of conditions had to be met for these plastics to have positive environmental impacts rather than exacerbating plastic pollution, climate change and biodiversity loss. “The commission’s new framework clarifies in what way these plastics can be part of a sustainable future,” it added.

In my view, it is important that the proposals, which must now be considered by the European Parliament and Council, are successful in their aims. The commission says a circular economy of packaging will help decouple economic development from the use of natural resources, contribute to achieving climate neutrality by 2050 and halting biodiversity loss, and reduce the EU economy’s dependency on many materials. Specifically, it estimates that by 2030 its proposed measures would bring greenhouse gas emissions from packaging down to 43 million tons compared to 66 million tons if the legislation is not changed. (Detailed impact assessment documents can be accessed at https://bit.ly/42cYEXd.)
Impacting Industry
These proposals, which are said to be aimed at creating a level playing field of packaging that is not more trade restrictive than necessary to fulfill the environmental objectives, will impact all companies working within the EU and those selling into the region, including those working within the tobacco and nicotine industries, though some exemptions apply to small companies. The use of packaging is universal, and the materials covered by the proposals include aluminium, cardboard, ceramics, glass, metal, paper, plastic, porcelain, stoneware, textiles and wood.
But, just to be certain where the tobacco industry would stand, I wrote to the commission asking if I would be correct in assuming that all the proposals finally accepted by the parliament and council would apply to the tobacco industry, in respect of both its leaf tobacco and its product (including new-generation products) packaging.
Interestingly, the commission chose to answer a different but related question by saying, “The tobacco industry would certainly [my emphasis] not be exempt from these rules according to our proposals.” I thought this answer, apart from being a little sniffy, was interesting because it seemed to assume that, despite a history of disadvantages being heaped on tobacco industry packaging, I had been wondering whether the industry could, suddenly and miraculously, expect to be advantaged by being exempted from some of the proposed rules.
In fact, my thoughts had been going in another direction. I had been wondering whether the tobacco industry and its much put-upon consumers might be well served by being treated equally with other industries for once. As I understand it, the commission proposals, in part, are about incentivizing innovation, something the industry might want to examine.
Buying in Bulk
If the proposals applied across the board, the tobacco products industry might, for instance, be encouraged to participate in refillable initiatives, which are mentioned in the proposals as a way of reducing the use of packaging materials. It could be imagined that, under such a scheme, cigarette consumers might buy from their local store cigarettes obtained from bulk packs and taken away in reusable containers. Clearly, with the exception of the bulk packs, which would be seen only by a limited number of people, possibly mainly nonsmokers, this would put paid to the grotesque health warnings that smokers, unlike alcohol drinkers, have to endure.
I cannot imagine the tobacco industry being allowed to apply such a system given that it has in the past been dissuaded, both by external or, rather more shockingly, internal forces, from introducing environmental incentives into its packaging because of the idea that, in the mind of consumers, environmental claims equal health claims. This idea, I suspect, would be impossible to defend, but it persists.
But why should the industry not be allowed to apply such a system? Where is the moral line to be drawn here? Is it right for the commission, despite what it says, to apply exemptions to the tobacco industry? Is it defensible for the commission to hang onto these health warnings, which have dubious moral or practical underpinnings, in an attempt to dissuade smokers from continuing with their habit? Remember, to disallow such a tobacco industry initiative would, in the commission’s view, discourage the use of more environmentally friendly packaging and thereby make the world a riskier place for everybody.
Certainly, if it does decide to disadvantage the tobacco industry, it should do the same with any number of other industries, such as the automotive industry, which destroys lives in much the same way (and other ways) as the tobacco industry is said to destroy lives. Sections of the automotive industry, too, have been deceptive about the risks caused by the use of their products and, in their case, about the extent to which such use endangers the public at large rather than just the users of their products.
Action Needed
Having said that, while I do not work in packaging and cannot speak for the practicality or efficaciousness of individual proposals, it is clear to me that action needs to be taken in respect of the three stated objectives of the proposed revisions. Firstly, to prevent the generation of packaging waste by reducing it in quantity, restricting unnecessary packaging and promoting reusable and refillable packaging.
Secondly, to boost high-quality (“closed loop”) recycling by making all packaging on the EU market recyclable in an economically viable way by 2030. And thirdly, to reduce the need for primary natural resources by creating a well-functioning market for secondary raw materials and increasing the use of recycled plastics in packaging through mandatory targets.
I like the emphasis on preventing wherever possible the generation of packaging, though it is important to note the commission makes clear that packaging plays a vital role in protecting and preserving products.
I also like the commission’s emphasis on having clear and consistent labeling on every piece of packaging to indicate what it is made of and to what waste stream it should go. This is not the case currently. The commission, in its proposals, makes the point that regulatory approaches differ from one member state to another, which means that, for instance, labeling requirements differ.
One concern has to be whether the new rules can be made to work, because previous rules haven’t, at least not satisfactorily. The commission says that its directive on packaging and packaging waste (94/62/EC – PPWD), which, under the latest proposals, is due to be repealed, was a regulatory failure that cannot be remedied simply by better enforcement of the current rules. Moreover, the commission added, the available data hinted that neither measures undertaken by the member states based on the current PPWD nor those based on the ORD [2020 Own Resource Decision] or SUPD [2019 Single-Use Plastic Directive], both of which would be amended under the proposals, were sufficient to ensure that they met all the specific targets for the recycling rates set out in the PPWD.
In trying to make the proposed rules more effective, the commission is aiming for them to be bound up in a regulation rather than in a directive, which seems to be a step in the right direction. Regulations are binding legal acts that must be applied in their entirety throughout every member state whereas directives are legislative acts that set goals that all states must achieve but that allow room for individual states to devise their own laws for achieving those goals.
Finally, the press note included a couple of comments, and in part, Virginijus Sinkevicius, the EU commissioner for Environment, Oceans and Fisheries, made the point that we had all at one time or another received products that, ordered online, had arrived in excessively large boxes. I’m sure there is a lesson to be learned from this claim, but I hope that such knowledge does not lead only to the examination of packaging, which is merely a symptom of a social problem. Tracking back to the cause will show, I think, that we need to examine, too, our buying habits. For those of us lucky enough to be able to do so, we should surely try to buy less stuff and only from shops to which we can walk or cycle carrying reusable containers—including elegant cigarette cases.
George Gay is Tobacco Reporter’s European editor, but his territory spans the globe. Based in London, George has covered the tobacco industry since 1982, initially for a U.K.-based publication and since 2004 for Tobacco Reporter. George’s understanding of industry issues, combined with his keen sense of observation and dry wit, have earned him a loyal following among Tobacco Reporter’s readers.

May 1, 2023